Pregnancy and Systemic Lupus Erythematosus

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


As SLE onset is often in young adulthood, pregnancy is common and is usually successful. Pregnancy, though, is considered high-risk due to a combination of maternal (lupus flare, diabetes, pre-eclampsia) and fetal (miscarriage, intrauterine fetal demise, preterm birth, intrauterine growth restriction, congenital heart block) risks. Pregnancy should be planned for a time of good control of SLE (on allowable medications). The antimalarial hydroxychloroquine should be continued. The only permitted immunosuppressive drugs are azathioprine and tacrolimus. Of the antiphospholipid antibodies, only the lupus anticoagulant has been associated with adverse pregnancy outcomes in the largest prospective multicenter study, Predictors of Pregnancy Outcome: Biomarkers in Antiphospholipid Antibody Syndrome and Systemic Lupus Erythematosus (PROMISSE). Management of antiphospholipid syndrome in pregnancy is low molecular weight heparin and aspirin, although only 75% of pregnancies are successful.

Original languageEnglish (US)
Pages (from-to)24-30
Number of pages7
JournalBest Practice and Research: Clinical Obstetrics and Gynaecology
StatePublished - Apr 2020


  • Antiphospholipid antibodies
  • Lupus anticoagulant
  • Lupus nephritis
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Obstetrics and Gynecology


Dive into the research topics of 'Pregnancy and Systemic Lupus Erythematosus'. Together they form a unique fingerprint.

Cite this